1997•PubMedRequires access

[Comparison of CHEP and CHOP chemotherapy in the management of non-Hodgkin's lymphoma].

J Chen, Z Wang

Open publisher page 1 citations

Abstract

OBJECTIVE: Therapeutic effect and toxicity of CHEP and CHOP chemotherapy in the treatment of non-Hodgkin's lymphoma (NHL) were compared. METHODS: From October 1989 to June 1996, comparison of 52 NHL was carried out: CHEP (cyclophol-sphamide, adriamycin, etoposide, prednisone) group-26 patients and CHOP(cyclophosphamide, adriamycin, vincristine, prednisone) group-26 patients. The responses and toxicities were compared by the chi 2 test. RESULTS: The CHEP group gave an overall response rate of 76.9%(20/26). In 10 untreated patients CR was observed in 7; The CHOP group gave an overall response rate of 65.4%(17/26). In 17 untreated patients CR was observed in 8(P > 0.05). Having been followed to the end of August, 1996, 16 patients in the CHEP group and 15 patients in the CHOP group were alive with respective median survivals 24(3-66) months and 20(2-48) months. Among the untreated patients, the 1-year disease-free survival (DFS) rates of those who gave CR were 70.0% and 23.5% (P < 0.05). 2-5 year DFS rats were 30%, 20%, 20%, 20%, and 11.8%, 5.9%, 5.9%, orespectively. The toxic reactions were tolerable in both groups. CONCLUSION: In untreated NHL patients as treated with CHEP chemotherapy, 1-year DFS rate was superior to that of CHOP regimen (P < 0.05). Side toxicities were comparable in both groups, but no peripheral neuritis was observed in the CHEP group.

About this research paper

What this paper is about

OBJECTIVE: Therapeutic effect and toxicity of CHEP and CHOP chemotherapy in the treatment of non-Hodgkin's lymphoma (NHL) were compared. METHODS: From October 1989 to June 1996, comparison of 52 NHL was carried out: CHEP (cyclophol-sphamide, adriamycin, etoposide, prednisone) group-26 patients and CHOP(cyclophosphamide, adriamycin, vincristine, prednisone) group-26 patients. The responses and toxicities were compared by the chi 2 test. RESULTS: The CHEP group gave an overall response rate of 76.9%(20/26). In 10 untreated patients CR was observed in 7; The CHOP group gave an overall response rate of 65.4%(17/26). In 17 untreated patients CR was observed in 8(P > 0.05). Having been followed to the end of August, 1996, 16 patients in the CHEP group and 15 patients in the CHOP group were alive with respective median survivals 24(3-66) months and 20(2-48) months. Among the untreated patients, the 1-year disease-free survival (DFS) rates of those who gave CR were 70.0% and 23.5% (P < 0.05). 2-5 year DFS rats were 30%, 20%, 20%, 20%, and 11.8%, 5.9%, 5.9%, orespectively. The toxic reactions were tolerable in both groups. CONCLUSION: In untreated NHL patients as treated with CHEP chemotherapy, 1-year DFS rate was superior to that of CHOP regimen (P < 0.05). Side toxicities were comparable in both groups, but no peripheral neuritis was observed in the CHEP group.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: Therapeutic effect and toxicity of CHEP and CHOP chemotherapy in the treatment of non-Hodgkin's lymphoma (NHL) were compared. METHODS: From October 1989 to June 1996, comparison of 52 NHL was carried out: CHEP (cyclophol-sphamide, adriamycin, etoposide, prednisone) group-26 patients and CHOP(cyclophosphamide, adriamycin, vincristine, prednisone) group-26 patients. The responses and toxicities were compared by the chi 2 test. RESULTS: The CHEP group gave an overall response rate of 76.9%(20/26). In 10 untreated patients CR was observed in 7; The CHOP group gave an overall response rate of 65.4%(17/26). In 17 untreated patients CR was observed in 8(P > 0.05). Having been followed to the end of August, 1996, 16 patients in the CHEP group and 15 patients in the CHOP group were alive with respective median survivals 24(3-66) months and 20(2-48) months. Among the untreated patients, the 1-year disease-free survival (DFS) rates of those who gave CR were 70.0% and 23.5% (P < 0.05). 2-5 year DFS rats were 30%, 20%, 20%, 20%, and 11.8%, 5.9%, 5.9%, orespectively. The toxic reactions were tolerable in both groups. CONCLUSION: In untreated NHL patients as treated with CHEP chemotherapy, 1-year DFS rate was superior to that of CHOP regimen (P < 0.05). Side toxicities were comparable in both groups, but no peripheral neuritis was observed in the CHEP group.

Key concepts: Medicine, CHOP, Vincristine, Gastroenterology, Prednisone, Internal medicine, Cyclophosphamide, Chemotherapy

Related papers

Back to paper searchBrowse research topicsOriginal source
[Comparison of CHEP and CHOP chemotherapy in the management of non-Hodgkin's lymphoma]. — Research Paper | ScholarLens